0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > BTN3A1

BTN3A1

Brief Information

Name:Butyrophilin subfamily 3 member A1
Target Synonym:BTF5,BTN3A1,CD_antigen,BTN3.1,BT3.1,DJ45P21.3 (Butyrophilin, Subfamily 3, Member A1),Butyrophilin, Subfamily 3, Member A1,CD277 Antigen
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

BT1-H82E4-ELISA
 BTN3A1 ELISA

Immobilized Anti-BTN3A123 Antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human BTN3A1 Protein, His,Avitag (Cat. No. BT1-H82E4) with a linear range of 0.1-4 ng/mL (QC tested).

BT1-H52H4-MALS-HPLC
BTN3A1 MALS images

The purity of Human BTN3A1 Protein, His Tag (Cat. No. BT1-H52H4) is more than 85% and the molecular weight of this protein is around 65-80 kDa verified by SEC-MALS.

Synonym Name

BTN3A1,CD277,BTF5

Background

Butyrophilin subfamily 3 member A1 (BTN3A1) is also known as CD277 and BTF5, which belongs to the immunoglobulin superfamily and contains one B30.2/SPRY domain and two Ig-like V-type (immunoglobulin-like) domains. BTN3A1 plays a role in T-cell activation and in the adaptive immune response. Also, BTN3A1 regulates the proliferation of activated T-cells and the release of cytokines and IFNG by activated T-cells. Furthermore, BTN3A1 mediates the response of T-cells toward infected and transformed cells that are characterized by high levels of phosphorylated metabolites, such as isopentenyl pyrophosphate.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ICT-01(Imcheck Therapeutics) ICT-01 Phase 2 Clinical ImCheck Therapeutics SAS Solid tumours; Neoplasms; Lymphoma Details
ICT-01(Imcheck Therapeutics) ICT-01 Phase 2 Clinical ImCheck Therapeutics SAS Solid tumours; Neoplasms; Lymphoma Details

This web search service is supported by Google Inc.

totop

Laisser un message